[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-nonadecanoyloxypropyl] nonadecanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-nonadecanoyloxypropyl] nonadecanoate
• 化学式: C₄₃H₈₆NO₈P
• 分子量: 776.131
• InChiKey: NPUNAOAZXGWGQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.5
• 重原子数：
  53
• 可旋转键数：
  45
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  丁二酸酐 、 [3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-nonadecanoyloxypropyl] nonadecanoate 在 吡啶 作用下， 生成 4-[2-[2,3-Di(nonadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethylamino]-4-oxobutanoic acid
  参考文献：
  名称：

  DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES

  摘要：

  The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.

  公开号：

  US20200297632A1

文献信息

• Delivery of agents to inflamed tissues using folate-targeted liposomes
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：US11185505B2

  公开（公告）日：2021-11-30

  The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.

  本发明所述的技术涉及一种叶酸受体靶向剂，包括用于治疗炎症性疾病的治疗性药物，所述叶酸受体靶向剂中包括含有被包封的治疗性药物的叶酸受体靶向脂质体（叶酸靶向脂质体），以及与治疗性药物偶联的叶酸受体靶向树枝状聚合物（叶酸靶向树枝状聚合物偶联物），所述脂质体和偶联物可用于治疗包括自身免疫性疾病在内的炎症性疾病。此外，本发明还涉及含有被包封的成像剂的叶酸靶向脂质体，以及与成像剂偶联的树枝状聚合物，它们在所述疾病的诊断和治疗监测中具有应用价值。
• CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME
  申请人：de los Rios Miguel

  公开号：US20110293725A1

  公开（公告）日：2011-12-01

  Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.
• SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM
  申请人：de los Rios Miguel

  公开号：US20140010885A1

  公开（公告）日：2014-01-09

  A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
• DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：US20200297632A1

  公开（公告）日：2020-09-24

  The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.